Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carmustine
Drug ID BADD_D00371
Description A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Indications and Usage For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Marketing Status approved; investigational
ATC Code L01AD01
DrugBank ID DB00262
KEGG ID D00254
MeSH ID D002330
PubChem ID 2578
TTD Drug ID D01OXI
NDC Product Code 54879-036; 43598-628; 70710-1525; 70860-223; 0781-3474; 50137-0686; 57821-002; 14593-823; 16729-545; 23155-790; 70121-1482; 76339-121; 50683-0017; 54893-0055; 68475-503; 57884-0032; 16729-548; 23155-649; 55718-139; 59651-168; 24338-050; 58621-002; 59981-034; 23155-261; 71288-126
UNII U68WG3173Y
Synonyms Carmustine | BCNU | N,N'-Bis(2-Chloroethyl)-N-Nitrosourea | FIVB | 1,3-Bis(2-Chloroethyl)-1-Nitrosourea | BiCNU | Nitrumon
Chemical Information
Molecular Formula C5H9Cl2N3O2
CAS Registry Number 154-93-8
SMILES C(CCl)NC(=O)N(CCCl)N=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia aspiration22.07.01.015; 11.01.09.019--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.000224%Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary hypoplasia22.10.01.002; 03.16.01.003--Not Available
Pyrexia08.05.02.0030.000504%
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.001--Not Available
Seizure17.12.03.0010.000504%
Sepsis11.01.11.003--
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin necrosis23.03.03.011--Not Available
Somnolence19.02.05.003; 17.02.04.0060.000280%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.003--Not Available
Status epilepticus17.12.03.0050.000112%Not Available
Stomatitis07.05.06.005--
Stupor19.02.05.004; 17.02.04.007--Not Available
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.007--Not Available
Teratogenicity03.02.01.004; 12.03.01.032--Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Tremor17.01.06.002--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Vasospasm24.04.02.002--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene